By John Vandermosten, CFA
NASDAQ:ACHV
READ THE FULL ACHV RESEARCH REPORT
Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported first quarter 2022 results in a press release and held a conference call after market close on May 12, 2022. The company concurrently filed its Form 10-Q with the SEC. Highlights for 2022 include impressive topline results from the ORCA-21trial, launch of the ORCA-3 trial, participation in various investor and scientific conferences and expansion of its manufacturing and quality and operations team and a board member addition.
Achievements for the first quarter ended March 31st and to-date include:
➢ ORCA-2 last subject, last follow up...
Login or create a forever free account to read this news
Sign up/Log in